To evaluate the efficacy and safety of 125 I seeds implantation for refractory chest wall (CW) metastasis or recurrence under CT guidance. In addition we assessed initial data obtained on the therapeutic response for refractory CW metastasis or recurrence. Twenty consecutive patients underwent permanent implantation of 125 I seeds (from Jul. 2004 to Jan. 2011 computed tomography (CT) guidance. Postoperative dosimetry was routinely performed for all patients. The actuarial D90 of the implanted 125 I seeds ranged from 100 Gy to 160 Gy (median:
Introduction
Chest wall (CW) metastasis or recurrence are more common than primary CW tumors (1) . Radical resection is in most cases the major component of treatment. Radiotherapy should be added when adequate margins cannot be achieved by surgery. Use of chemotherapy depends on primary tumor. While there are few data on the results of treatments of patients with CW metastasis or recurrence, especially those with metastasectomy, radiotherapy and chemotherapy before. In many cases, there is no alternative. Managements of these patients remains challenging.
The interstitial implantation of 125 I seeds, which is one of the most promising modalities of brachytherapy, has been successfully performed in many different Technology in Cancer Research & Treatment 2014 February 3. Epub ahead of print malignant tumors during the past 20 years. The 125 I seeds have a half-life (t1/2) of 59.4 days, a low X-ray energy level of 27.4-31.4 keV, and a half-value layer of 1.7 cm in tissue. We have previous reported a series of results regarding 125 I seeds implantation for pancreatic carcinoma (2) , re-recurrent rectal cancer (3) , recurrent head and neck carcinoma (4) , and so on, in which the beneficial seed implantation characteristics of safety, sustained accumulation of radiation, and homogenous dose distribution in the target area were presented.
The aim of this study was to evaluate the efficacy and safety of 125 I seed implantation for refractory CW metastasis or recurrence under CT guidance. In addition we assessed initial data obtained on the therapeutic response for refractory CW metastasis or recurrence.
Materials and Methods
From July 2004 to January 2011, 20 consecutive patients with CW metastasis or recurrence underwent interstitial permanent implantation of 125 I seeds under CT guidance at Peking University 3rd Hospital. In this retrospective study, we defined "chest wall" involving the sternum, ribs, costovertebral junction and soft tissue of the thoracic cage. All patients had been histologically proven malignant and without any evidence of other distant metastasis; a Karnofsky Performance Status (KPS) score 60; and no severe impairment of kidney, liver, or bone marrow function.
The patient characteristics are shown in Table I . Thirteen of the 20 patients were men and seven were women. Their ages ranged from 25 to 73 (median 54 years). Thirteen (4 of lung cancer, 2 of thymic carcinoma, 2 of renal cancer, 1 of cardiac carcinoma, 1 of melanoma, 1 of liver cancer and 2 of primary cancer unknown) were CW metastasis, the other seven (5 of breast cancer, 1 of chondrosarcoma and 1 of pleural mesothelioma) were CW recurrences. Everyone had receive at least one modality treatment before 125 I seed implantation. Nine patients had received salvage surgical treatment, fourteen had CW external beam radiation therapy (EBRT, the total cumulative doses of EBRT were 50-66 Gy, with a median of 56 Gy), and eleven had chemotherapy. Among them, 4 patients were diagnosed with local recurrence after surgery, EBRT and chemotherapy. Two patients received only radiotherapy and three received only chemotherapy and then relapsed. All patients had been reviewed by the surgeons and radiation oncologists, and were considered not suitable for salvage surgery and EBRT again, or the patients refused to receive salvage surgery/EBRT. The tumor volumes were measured using CT scans at 5-mm intervals 3-5 days before seed implantation. Radiation oncologist outlined the planning target volume (PTV) on each transverse image. The PTV included the gross tumor volume (GTV) and an extended margin of 0.5 cm. These tracings were digitized onto a computer treatment planning system (TPS) (3D-TPS, Beijing Fei Tian Industries Inc., Beijing, China) and used to define the target volume for which the D90 (the doses delivered to 90% of the target volume defined by CT using dose-volume histogram) of irradiation was prescribed. The total activity and the number of 125 I seeds implanted at the target site were determined using the TPS.
After the target volume was determined, interstitial needles (18 gauge) were inserted into the tumor under CT guidance with adequate local anesthesia. The needles were placed at a distance of 1 cm from each other and kept in a parallel array; precautions were taken to avoid severe skin reaction by placing the needles at a distance of 2 cm away from marginal skin. 125 I seed implantation was performed such that the GTV and a 0.5 cm tumor margin were covered. 125 I seeds were implanted using a Mick applicator, and the distance between the centers of any 2 seeds was maintained at approximately 1.0 cm. All the patients received perioperative prophylactic antibiotics.
Postoperative dosimetry was routinely performed for all the patients. The dose delivered by the implants was determined immediately by a 3-dimensional seed identification technique and 5-mm thick CT scans ( Figure 1 ). The CT-derived postimplant target volumes were determined such that they included the GTV and a 0.5 cm tumor margin. The contoured images and sources were entered into a computerized TPS software (Prowness-3D, SSGI, USA), and a redundancy check was performed to prevent seed duplication. The actuarial D90 over the period of total decay was 100-160 Gy ( 
Results
Among all the 20 patients, 3 patients had CR (15%), 12 patients had PR (60%). The 1-, 2-, 3-and 4-year tumor control rates ( Figure 3 ) were all 88.7% respectively. 2 (10%) patients died of local recurrence: One patient with chest metastasis size of 6.5311312.9 cm 3 primary lung cancer showed stable disease (SD) for 7 months and then died of local progression at 8 months after seed implantation. The other patient with 8.038.035 cm 3 diagnosed cardiac carcinoma also showed SD for 3 months and then local progression; the patient refused further therapy and died at 9 months after seed implantation. Of the 20 patients, mild neuropathy pain was observed in one case (5%), and mostly alleviated after symptomatic treatment. Grade 1 or 2 skin reactions were shown in 6 patients (30%) who had received EBRT before. No grade 3 and 4 skin or other side effects were observed. Rib fracture, ulceration, fibrosis, pneumothorax or hemopneumothorax were not seen (Tables II & III) .
Discussion
The morbidities of hematogenous metastasis or recurrence varied with different histology subtypes. Data from large, randomized trials have demonstrated that locoregional recurrences occur in approximately 5-15% of patients despite receiving adjuvant EBRT after mastectomy or breastconserving surgery (5). Wouters et al. (6) have reported that 86% of patients diagnosed with CW sarcoma with irradical resections would recur. It is especially true in the recurrent group that 93% of irradical resections were followed by rerecurrence. Generally, surgical resection is the treatment of choice for palliation from pain or chronic ulceration, and often is be preceded or followed by radiotherapy or chemotherapy. The available literature consists of a number of series, most of which are small, often with mixed differentiation (sarcoma/carcinoma) histologic subtypes. Warzelhan et al. (7) reported 82 consecutive patients with tumors of the CW; the following subgroups were defined according to the histology: (A), sarcoma (n 5 32); (B), breast cancer (n 5 22); (C), renal cell cancer (n 5 9); (D), other metastases (n 5 7); (E), miscellaneous (n 5 12). Among them, group A and B showed 5-year overall survival rate of 58% and 58% respectively, while the other groups showed lower survival rates. The impact of the histology on survival is not neglectable. There was a significant difference in survival (7) between sarcoma and carcinoma patients. Recently a retrospective review of 76 patients who underwent CW metastasectomy over a 17-year period showed that the overall 5-year survival of this group was 40% 1 . In our study, 20 patients of various differentiation of CW metastasis or recurrence with 1-and 2-, 3-, 4-year OS were 53.3% and 35.6%, respectively, with a median survival of 15 months (95% CI, 7.0-22.9). Because of multiple pathological differentiation, especially of metastasis of lung, renal cancer and so on, the results of OS rate shown in our study were not as promising as local control, as expected.
Resection of such tumors requires appropriate repair of the defect and reconstruction of the integument. Although with the progression of surgical technique, CW tumor resection is selectively possible with a risk of perioperative mortality from 0 to 4.5% (8) (9) (10) . The significance of long-term results of surgical treatment for metastatic lesions often ranks beyond the alleviation of symptoms like pain, necrosis, and ulceration. In addition, only a small portion of the patients have the chance of salvage surgical resection, and most patients usually have already undergone previous radiotherapy of the affected area. In many cases, to these patients with refractory CW metastasis or recurrence, there is no alternative treatment in many institutions.
EBRT is routinely performed for CW metastasis and recurrence as one of the palliative treatments. But there are publications on EBRT for CW metastasis other than CW recurrence of breast cancer. The main reason is due to consideration of CW toxicity including skin changes (erythema, ulceration and fibrosis) (11) , CW pain (focal or neuropathic) (12, 13) , and rib fracture (symptomatic and asymptomatic) (14) (15) (16) . Stereotactic Body Radiation Therapy (SBRT) with its merits of dosimetry has been used for peripheral lung cancer recently. Several studies showed incidence of late CW toxicity after SBRT reporting wide variation ranging from less than 5% to as high as 25% (17).
Stephans et al. (18) reported that restricting V30 to less than 30 cm 3 and V60 to less than 3 cm 3 should result in less than 10% to 15% risk of CW toxicity. However, tumor coverage and other normal tissue constraints should not be compromised. They further confirmed the restrictions on EBRT for CW lesions.
Repeat radiation is a rarely used treatment strategy for CW tumors reported only in cases of recurrence of breast cancer. Treating CW recurrences after mastectomy with re-surgery alone provides limited local control for one-third of patients (19) . The routine addition of a second radiotherapy series is accompanied by major concerns regarding side effects, as cumulative radiation doses reach or exceed 100 Gy, which may lead to an increased rate of late complications. The clinical outcomes of CW re-irradiation (with or without concurrent hyperthermia) reported in published studies have varied widely, with CR rates of 20-71% (20, 21) , and 1-year disease free survival (DFS) rates of 66-85% (5) . Moderate or marked skin toxicity of CW re-irradiation was reported. 14% (22) of skin ulceration incidence had been noted in the literature.
To our knowledge, there have been no articles on brachytherapy for CW metastasis or recurrence up to now. Interstitial permanent implantation of 125 I seeds under CT guidance is introduced for the first time in this study. When 125 I seeds are implanted, the dose is concentrated in the immediate surrounding tissues, sparing adjacent normal structures and medical personnel. Additionally, the relatively long half-life (59.4 days for 125 I seeds) leads to prolonged radiation exposure to the implanted tumor volume, allowing approximately 95% of the needed dose to be delivered within a year (23) . The therapeutic benefit may be theoretically enhanced by consequent increases in local dose after radiation-induced tumor shrinkage brings the 125 I seeds closer together (24) . Finally, by providing continuous low-dose irradiation, 125 I may decrease the oxygen enhancement ratio, which may improve the efficacy in hypoxic portions of the tumor (25) . Interstitial permanent implantation of radioactive seeds into the tumor site provides the advantage of delivering a high dose of irradiation to the tumor (range 100-160 Gy), which drops off sharply outside the local implanted field. The beneficial seed implantation characteristics of safety, sustained accumulation of radiation, and homogenous dose distribution in the target area were represented.
Conclusion
Interstitial permanent implantation of 125 I seeds under CT guidance appears feasible, efficacious, and safe for refractory CW metastasis or recurrence. This promising technique provides a minimally invasive procedure, offers the advantages of preciseness, acceptability to patients, safety and ease of implementation. The long-term results of this procedure are still under investigation.
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